Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells
November 10, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
November 08, 2021 02:00 ET
|
Autolus Therapeutics plc
– One of the largest private financings of a UK biotech company, and the largest from a single source – continues Blackstone conviction in the country – Durability and favorable toxicity profile of...
Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition
November 04, 2021 09:01 ET
|
Autolus Therapeutics plc
- Demonstrates progress on the Company’s commercial manufacturing process and builds on positive obe-cel clinical data presented at EHA Conference Call and Webcast to be held Tuesday, December 14,...
Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress
November 03, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3
October 25, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK
September 16, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
September 15, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to participate in upcoming virtual investor conferences
September 02, 2021 07:00 ET
|
Autolus Therapeutics plc
- Goldman Sachs Eleventh Annual Biotech Symposium on September 7- 2021 Virtual Wells Fargo Healthcare Conference on September 10 at 7.30am ET - H.C. Wainwright & Co 23rd Annual Global Investment...
Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology
September 01, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
August 09, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...